Valuation: Pulmonx Corporation

Market Cap 78.6M 70.19M 64.84M 58.76M 110M 7.46B 112M 780M 309M 3.91B 295M 289M 12.32B P/E 2026 *
-1.75x
P/E 2027 * -1.94x
Enterprise Value 78.6M 70.19M 64.84M 58.76M 110M 7.46B 112M 780M 309M 3.91B 295M 289M 12.32B EV / Sales 2026 *
0.87x
EV / Sales 2027 * 0.8x
Free-Float
95.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.66%
1 week+2.81%
Current month-4.19%
1 month-8.50%
3 months+50.00%
6 months+42.97%
Current year-17.19%
1 week 1.74
Extreme 1.745
1.89
1 month 1.72
Extreme 1.72
2
Current year 1.13
Extreme 1.13
2.59
1 year 1.13
Extreme 1.13
2.89
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 27/10/2025
Director of Finance/CFO 53 01/05/2019
Chief Tech/Sci/R&D Officer - 01/03/2020
Director TitleAgeSince
Director/Board Member 72 01/02/2007
Chairman 66 01/10/2019
Director/Board Member 64 18/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 A Sell

Chief Technology Officer

-14,245 0.0332%
9/1/26 A Sell

Chief Executive Officer

-41,882 0.0975%
9/1/26 A Sell

Executive/Senior Manager

-7,879 0.0183%
Change 5-day change 1-year change 3-year change Capi.($)
-2.66%+2.81%+15.09%-78.67% 78.6M
+1.16%-1.13%-17.92%+8.27% 179B
+0.02%+4.24%-19.82%+16.53% 118B
-1.22%+0.70%+1.27%+31.80% 117B
+2.29%+17.36%-41.94%+9.49% 93.26B
-2.21%-2.91%+0.74%+75.30% 63.16B
-1.06%+1.75%+13.50%+80.00% 55.68B
-0.75%+3.73%+6.64%-22.28% 54.18B
-1.13%+0.00%-12.25%+31.02% 44.15B
+0.17%+5.85%-4.92%-10.64% 33.95B
Average -0.54%+3.41%-5.96%+14.08% 75.85B
Weighted average by Cap. -0.00%+3.09%-11.68%+22.46%

Financials

2026 *2027 *
Net sales 90.55M 80.86M 74.7M 67.69M 127M 8.6B 129M 899M 356M 4.5B 340M 333M 14.2B 98.31M 87.79M 81.11M 73.5M 138M 9.33B 140M 976M 386M 4.89B 369M 361M 15.42B
Net income -44.24M -39.5M -36.49M -33.07M -61.87M -4.2B -62.89M -439M -174M -2.2B -166M -162M -6.94B -40.71M -36.36M -33.59M -30.44M -56.95M -3.86B -57.89M -404M -160M -2.02B -153M -150M -6.38B
Net Debt - -
Projected Income Statement - Annual - Pulmonx Corporation
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
23/10/26 $1.830 -2.66% 227,767
22/10/26 $1.880 +2.73% 131,553
21/10/26 $1.830 +0.55% 176,675
20/10/26 $1.820 +4.00% 525,792
19/10/26 $1.750 -1.69% 220,309
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Pulmonx Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.830USD
Average target price
3.400USD
Spread / Average Target
+85.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pulmonx Corporation
  1. Stock Market
  2. Stocks
  3. LUNG Stock